About 1–10% incidence of immune-related endocrinopathies in NSCLC has been seen with anti-PD-1 and PD-L1 inhibitors, while combination therapy including CTLA-4/PD-(L)1 antibodies was noted to have an incidence of 11–23% [63]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.